Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city-a retrospective 14-year study

Página do item simplificado
dc.contributor.authorSouza, E. M. [UNIFESP]
dc.contributor.authorBaiocchi, Otavio Carvalho Guimarães [UNIFESP]
dc.contributor.authorZanichelli, M. A. [UNIFESP]
dc.contributor.authorAlves, A. C. [UNIFESP]
dc.contributor.authorOliveira, J. S. R. [UNIFESP]
dc.contributor.institutionHigienopolis São Paulo
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T13:52:40Z
dc.date.available2016-01-24T13:52:40Z
dc.date.issued2009-07-01
dc.description.abstractThe behavior of Hodgkin's lymphoma (HL) is different in developing countries, perhaps due to differences in epidemiology and population access to health care. We performed a retrospective study comparing the efficacy of mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPPABV) versus adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy protocols as first-line therapy for HL in a Brazilian population. A hundred and eighty-six HL patients were retrospectively analyzed regarding their first-line treatment with MOPPABV and ABVD at two public hospitals in SA o pound Paulo, Brazil. Eligible patients were either previously untreated or at first relapse after being treated with only radiotherapy with confirmed HL diagnosis. At a median follow-up of 9 years, complete remission is 89.5 and 85.9 (P = 0.3), overall survival 93.8% and 89.6% (P = 0.68), disease-free survival 85.6% and 81.6% (P = 0.41), and relapse ratios 20.9% and 26.4% (P = 0.17) for ABVD and MOPPABV, respectively. Extended-field radiation therapy postchemotherapy was mostly used in the MOPPABV group. There were three cases of secondary neoplasm (colon adenocarcinoma, myeloid chronic leukemia, and non-Hodgkin's lymphoma), all associated with MOPPABV. ABVD and MOPPABV protocols as first-line treatment for HL resulted in similar therapeutic outcomes and did not influence overall survival, disease-free survival, and relapse ratio. MOPPABV was related to a higher risk of secondary malignancy and, therefore, ABVD should be considered a better option for HL therapy. These findings corroborate recent data in literature.en
dc.description.affiliationHigienopolis São Paulo, BR-01240001 São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Dept Oncol Clin & Expt, BR-04024001 São Paulo, Brazil
dc.description.affiliationHEB, Brigadeiro State Hosp São Paulo, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Oncol Clin & Expt, BR-04024001 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent633-637
dc.identifierhttp://dx.doi.org/10.1007/s00277-008-0635-0
dc.identifier.citationAnnals of Hematology. New York: Springer, v. 88, n. 7, p. 633-637, 2009.
dc.identifier.doi10.1007/s00277-008-0635-0
dc.identifier.issn0939-5555
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/31630
dc.identifier.wosWOS:000266260300005
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofAnnals of Hematology
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.springer.com/open+access/authors+rights?SGWID=0-176704-12-683201-0
dc.subjectHodgkin's Lymphomaen
dc.subjectChemotherapyen
dc.subjectOverall survivalen
dc.titleComparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city-a retrospective 14-year studyen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos